Daewoong Pharmaceutical Announces New Drug Development Strategy in the US

[Asia Economy Reporter Choi Dae-yeol] Daewoong Pharmaceutical announced on the 9th that it will participate in the JP Morgan Healthcare Conference held in San Francisco, USA, for four days starting on the 13th, where it will reveal its overseas expansion strategy and new drug development roadmap.

At this internationally prestigious conference in the pharmaceutical and biotechnology fields, Daewoong Pharmaceutical will disclose these details on the 15th (local time). Key executives from the research and global divisions, including President Jeon Seung-ho of Daewoong Pharmaceutical, will attend. President Jeon will present the global strategy and R&D vision at the Emerging Market Track, which introduces companies growing in emerging countries. He will share the status of Nabota's expansion, which was the first domestic botulinum toxin to enter the US and European markets, as well as the establishment of a joint venture with the UK company Abacta for the development of immune disease treatments.

They will also announce the global clinical plan for Pexuprazan, a next-generation treatment for gastroesophageal reflux disease. Pexuprazan completed Phase 3 clinical trials in Korea last year and has applied for marketing authorization with the Ministry of Food and Drug Safety. Additionally, they will provide updates on the development of DWP212525, an autoimmune disease treatment prepared as the world's first innovative new drug, and DWN12088, a treatment for idiopathic pulmonary fibrosis. President Jeon stated, "We will actively promote the competitiveness of the Korean pharmaceutical industry to healthcare industry stakeholders and investors worldwide."